BioCentury
ARTICLE | Product Development

Dec. 3 Quick Takes: Recordati buying EUSA

Plus Sobi, BMS, Valneva, Sylvant and more

December 4, 2021 2:54 AM UTC

Italian pharma Recordati S.p.A. (MTAA:REC) will acquire EUSA Pharma Ltd. for €750 million ($845.7 million). EUSA Pharma’s drug products include anti-GD2 mAb Qarziba dinutuximab, indicated for high-risk neuroblastoma, anti-IL-6 mAb Sylvant siltuximab, indicated for idiopathic multicentric Castleman’s disease, and Fotivda tivozanib, a small molecule tyrosine kinase inhibitor of VEGF receptors 1, 2 and 3 that treats advanced renal cell carcinoma. The transaction is anticipated to close in 1H22. Recordati is majority owned by CVC Capital Partners.

AstraZeneca plc (LSE:AZN; NASDAQ:AZN) blocked the takeout of Swedish Orphan Biovitrum AB by withholding its 8% stake, which it gained in 2018 after granting SOBI U.S. rights to commercialize RSV drug Synagis palivizumab. SOBI accepted Advent International and Singapore wealth fund GIC’s takeout offer in September that was conditional on getting 90% of shares; the shareholders only tendered 87%, a Bloomberg report said. Advent and GIC withdrew their $8 billion public offer...